FindTrial
Sign In

Incidence of Gene mutation in Lung Cancer

Profiling the incidence of ROS1 alteration discovered in human Non Small Cell Lung Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/07/009024
Enrollment
400
Registered
2017-07-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Lung Cancer patients found to be positive for ROS1 and are treatment naïve

Interventions

Intervention1: Not Applicable: Not Applicable Control Intervention1: Not Applicable: Not Applicable

Sponsors

Tata Memorial center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1)Male or female patients aged >=18 years and 2)Histologically confirmed Non Small Cell Lung (NSCLC) Adenocarcinoma. 3)Tissue available for analysis. 4)Treatment naïve patients.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1)Patient unable to give consent. 2)Patients with Squamous Non-Small Cell Lung Cancer, small cell or large cell cancer. 3)Tumor tissue samples older than 5 year period or samples not properly stored. 4)Insufficient tissue samples with less tumor cells & high amount of necrosis.

Design outcomes

Primary

MeasureTime frame
To Estimate the prevalence of ROS1 mutation in 400 Indian Non Small Cell Lung Adenocarcinoma patient population.Timepoint: 2-3 years—

Secondary

MeasureTime frame
To analyse the efficacy and safety of crizotinib in Non Small Cell Lung Adenocarcinoma patients who are ROS1 rearranged.Timepoint: 2-3 years—

Countries

India

Contacts

Public ContactDr Kumar Prabhash

Tata Memorial Hospital

kprabhash1@gmail.com9167760576

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026